R&D Mind the gap: The need for gender-specific outcome measureme... It is well documented that women face delayed diagnoses, mischaracterised symptoms, and experience more years of ill-health compared to men.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.